Revolution Medicines secures first broad RAS approval in pancreatic cancer
The FDA cleared Revolution Medicines' RASONQUE on August 26, making it the first broad RAS-targeted therapy for metastatic pancreatic adenocarcinoma.
Boehringer Ingelheim
Every Fin-node story mentioning Boehringer Ingelheim — 1 story, newest first.
Boehringer Ingelheim · 1 story